2. Is Divis Laboratories Ltd undervalued or overvalued?
The key valuation ratios of Divis Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
3. Is Divis Laboratories Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Divis Laboratories Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
10 Year X-Ray of Divis Lab:
Analysis of Financial Track Record
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Divis Laboratories Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation ⓘ
Value Creation Index Colour Code Guide
ⓘ
Mar'15
Mar'16
Mar'17
Mar'18
Mar'19
Mar'20
Mar'21
Mar'22
Mar'23
Mar'24
TTM
ROCE % ⓘ
33.1%
35.6%
28.8%
21.7%
28.5%
25.4%
32.1%
35.1%
19.4%
16.5%
-
Value Creation Index ⓘ
1.5
2.2
1.6
0.9
1.5
1.3
1.9
2.1
0.7
0.5
-
Growth Parameters ⓘ
Growth Parameters Colour Code Guide
ⓘ
Sales ⓘ
3,115
3,776
4,064
3,891
4,946
5,394
6,969
8,960
7,767
7,845
9,360
Sales YoY Gr.
-
21.2%
7.6%
-4.3%
27.1%
9.1%
29.2%
28.6%
-13.3%
1%
-
Adj EPS ⓘ
32.2
41.5
41
32.5
50.2
49.4
75
110.5
65.3
59.6
82.5
YoY Gr.
-
28.9%
-1.4%
-20.7%
54.5%
-1.5%
51.8%
47.4%
-40.9%
-8.8%
-
BVPS (₹) ⓘ
131.7
161.7
201.8
223.2
262.1
275.4
350.2
441.8
481.8
512.1
563.9
Adj Net Profit ⓘ
855
1,102
1,087
862
1,331
1,311
1,990
2,933
1,734
1,582
2,191
Cash Flow from Ops. ⓘ
826
1,038
1,150
776
954
1,216
1,947
1,912
2,459
1,261
-
Debt/CF from Ops. ⓘ
0
0
0
0.1
0.1
0
0
0
0
0
-
CAGR ⓘ
CAGR Colour Code Guide
ⓘ
9 Years
5 Years
3 Years
1 Years
Sales ⓘ
10.8%
9.7%
4%
1%
Adj EPS ⓘ
7.1%
3.5%
-7.4%
-8.8%
BVPSⓘ
16.3%
14.3%
13.5%
6.3%
Share Price
21.5%
22.8%
21%
57.2%
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide
ⓘ
Mar'15
Mar'16
Mar'17
Mar'18
Mar'19
Mar'20
Mar'21
Mar'22
Mar'23
Mar'24
TTM
Return on Equity % ⓘ
26.5
28.3
22.5
15.3
20.7
18.4
24
27.9
14.2
12
15.3
Op. Profit Mgn % ⓘ
37.7
37.7
36.6
32.6
37.9
33.9
41.2
43.3
30.5
28.2
31.7
Net Profit Mgn % ⓘ
27.5
29.2
26.7
22.2
26.9
24.3
28.6
32.7
22.3
20.2
23.4
Debt to Equity ⓘ
0
0
0
0
0
0
0
0
0
0
0
Working Cap Days ⓘ
297
245
268
371
307
294
247
239
293
277
178
Cash Conv. Cycle ⓘ
173
156
144
154
142
153
126
130
182
183
153
Recent Performance Summary
Sales growth is good in last 4 quarters at 19.71%
Return on Equity has declined versus last 3 years average to 15.30%
Sales growth has been subdued in last 3 years 4.02%
Net Profit has been subdued in last 3 years -7.36%
Divi’s Laboratories is a leading Indian pharmaceutical company renowned for its expertise in manufacturing active pharmaceutical ingredients (APIs) and intermediates. Founded in 1990 by Dr. Murali K. Divi, the company has grown to become a significant player in the global pharmaceutical industry, supplying products to over 95 countries. Divi’s Laboratories operates through two main divisions, one focusing on generic APIs, including nutraceuticals, and the other on custom synthesis of APIs and intermediates for global innovator companies. With a strong emphasis on research and development, the company boasts state-of-the-art manufacturing facilities that adhere to stringent quality standards, ensuring the production of high-quality pharmaceutical ingredients. In FY24, the company earned a revenue of Rs. 7845 crores, with exports accounting for 87%, and the segmental split between generics and custom synthesis was 55%/45%.
Financial Performance
The financial performance of the company shows that the recent performance of the company is worse than the long term performance. Between FY22 and FY24, the company has faced significant challenges in both revenue and profitability, across all the main line items. Overall revenue fell by 12%, while EBITDA and PAT fell by 43% and 46% respectively. While this may look like erosion in business quality, the financial performance mainly shows that aftermath of the high demand witnessed during the Covid-19 pandemic. In the long term, the company’s performance is expected to normalise through margin reverting back to mean and revenue growing in double digits as a result of investments.
Business Segments:
a. Generic APIs:
The company is one of the leading players in the global Active Pharmaceutical Industry. In this segment, the company’s strategy is to focus on few molecules but high market share, which would lead to lower pricing pressure. As a result, Divi’s is the world’s largest manufacturer for multiple APIs such as Naproxen, Dextromethorphan, Gabapentin, Valsratan and Levetiracetam, which account for about 65% of total API sales. In Naproxen, Dextromethorphan and Gabapentin each, the company has a 60-70% market share, and in Levodopa, Pregabalin, Carbidopa and Mesalamine, the company has a 20-30% market share. Divi’s is one of the top 2 API manufacturers in the world for 18 out of the 30 molecules. The company constantly innovates at the technological level to produce products at lower costs, to be more competitive and gain a stronger market share.
This strategy allows the company to have more pricing power than its competitors along with higher demand visibility. However, the API division faces pricing pressure from time to time, as witnessed in the last 3 years. Such pricing pressures occur due to inventory destocking at the client level, which impacts sales and prices, and raw material price increases, which lead to a reduction in margins.
The company adds new products as drugs lose patent protection. Patent expiries tend to be lumpy as the number of high value drugs losing patent protection varies year to year.
The generic API division has a lower margin than the custom synthesis business, but has strong competitive advantages due to the company’s high market share in key products.
Nutraceuticals:
Nutraceuticals is a part of the Generic API business. Divi’s Laboratories' nutraceutical business focuses on the development and production of high-quality nutritional ingredients and supplements that promote health and wellness. In FY24, the business accounted for 9% of total revenue and 17% of the generic API business. The product portfolio includes a complete set of Carotenoids such as Beta Carotene, Astaxanthin, Lycopene, Canthaxahnthin as well as other finished forms such as Lutein, Vitamins (A, D3, D2, E Acetate and A Palmitate).
b. Custom Synthesis:
Divi’s Laboratories' custom synthesis business focuses on providing tailored solutions for the production of active pharmaceutical ingredients (APIs) and intermediates for global innovator companies. This division collaborates closely with pharmaceutical companies during the drug development process, offering expertise in complex chemical synthesis, process optimization, and scale-up production. Divi’s has a competitive advantage due to its strong technical knowhow and the low lag time for manufacturing.
In FY22, the company got a one-time Covid-19 related contract for the producing Molnupiravir from MSD, a leading pharmaceutical company. As a result, the sales for the division increased by 90% in FY22, and fell subsequently.
The Custom Synthesis division has a higher gross margin and the lack of growth from this segment in FY23 and FY24 has significantly impacted margins.
Future Prospects:
Capex: The company’s Kakinada facility should be operational in and after Q3FY25. The facility spans 500 acres, of which only 200 acres will be utilised in Phase 1. The investment in this facility is expected to be around Rs. 1500 crores. This would inevitably lead to higher revenue in the future without delays for additional capital expenditure.
Patent Expiry: Over the next 5 years, a large number of drugs will face patent expiry, creating a $200 billion opportunity for pharmaceutical players. As a result, Divi’s has a large opportunity to provide APIs for these now off patent drugs, leading to an increase in revenue.
Revival in Custom Synthesis: The custom synthesis segment will continue to fuel the company’s growth. The company has announced a long-term supply agreement with an MNC and is planning a capacity addition with an estimated investment between Rs. 650 crores to Rs. 700 crores, which will be funded from internal accruals. The proposed facility is expected to be operational by January of 2027.
Sartans: Sartans, also known as angiotensin II receptor blockers (ARBs), are a class of medications primarily used to manage hypertension (high blood pressure) and heart failure. The company is able to produce Sartans with extremely low levels of impurities which gives the company a competitive edge. These products are a part of both generic API and custom synthesis segments.
Contrast Media: The company has made inroads into contrast media chemistry, which is used for MRIs and CT Scans. While Iodine is used for CT scans, Gadolinium is used for MRI scans and the markets are worth around $5 billion and $4-4.5 billion each respectively. These product baskets will be a part of generics as well as custom synthesis. The customers contrast media APIs are extremely concentrated. The company has iodine recovery technology that reduces its raw material cost while showcasing greener technology usage, which gives it a competitive advantage.
Risks:
Raw Material Risk: The company is not immune to raw material price risks. In FY23, solvents, lithium and iodine prices increased drastically. The company faced pricing pressure in its generic API business as a result. However, the company is backward integrated which reduces its raw material risk. Additionally, the custom synthesis business has higher resilience to raw material price volatility.
Demand Risk: As the company already has the largest market share in certain products, the incremental growth rate in such products can be low. The company’s growth plans include growth in new products and end markets such as contrast media and sartans, which reduces the risk of demand saturation at the company level.
Compliance Risk: Divi’s Laboratories faces compliance risk from regulatory agencies, mainly from the FDA (USA). While the company has faced issues in the past, the company’s high global market share in certain products and quick resolution showcase the strong compliance culture at the company.
Divis Laboratories: Q4FY23 Result Update - 26 May 2023
Particulars
Q4FY23
YoY Growth
Revenue
1,951
-22.5%
EBITDA
488
-56%
EBITDA Margin
25.2%
-18.86%
PAT
321
-64.1%
Despite increase in sales sequentially, margins disappointed on account of high inventory cost and elevated pricing pressure in generic APIs. Overall weak numbers.
Results: Divi’s Lab reported 28.7% growth in sales and 59% growth in operating profit year on year. The revenue growth was aided by strong growth across the API and custom synthesis business.
We recommend tracking operating cash flow of Divis’ lab versus PAT as it has large working capital requirement in terms of inventories.
Revenue from generic API segment stood at 60% of sales, while that from custom synthesis stood at 40%. Going ahead, the company plans to have a mix between both the segments of around 50:50.
The share of revenue from the developed markets of the US and Europe stood at 71% for the quarter, while the share of exports stood at 90%. For the full year FY21, the exports constituted around 88% of sales.
The company has identified new areas, which would fuel growth going ahead; and this includes the next set of 10 molecules, which have gone off patent and offer a sizeable growth opportunity.
For its new generic molecules, validation and regulatory submission are under process. And on manufacturing front, the company operated at 86% operating capacity.
The company has declared a dividend of Rs. 20 for FY21.
Outlook: As per the management, the company faced logistical challenges due to the ongoing pandemic and blank sailing. Due to the investments made in the backward integration to basic chemicals for most of its generic API and diversified supplier base, it overcame most of its procurement issues.
Divis is an authorized manufacturer of MSD's (Merck Sharp & Dogme) Molnupiravir API and supplier of the same to MSD's voluntary licensing (VL) partners in India. Additionally, it has created one more stream in unit 1 to produce the same for which validation has begun and commercial production is expected to start in the coming quarters.
Divis Labs has almost doubled its capacity this led to the sales growth. As of end of FY21, the capital work in progress stood at ?710.6 crore. During the year, it took a project to fast-track its customs synthesis segment and the capex for the same was ~?400 crore. The immediate capex for the construction of its Kakinada plant is expected to be ?600 crore.
MoneyWorks4me Opinion: We had recommended BUY on Divis Labs at 650/share.
We had recommended Divis Labs and Syngene before market started recognising their long term potential. Today market is exuberant on the other extreme, it is pricing them as if nothing can go wrong.
While customer synthesis and API manufacturing are growth businesses, the growth comes at a cost of reinvestment in plants and inventories. We believe that current prices assume no reinvestment.
Even after assuming 25% growth over next 2 years, Divi’s labs trades at steep 39x EV/Operating Cash flow with leaves very limited margin of safety.
We had recommended 50% SELL recommendation on Divi’s near 1600/share based on then expected growth rate. However, benefits from supply chain moving out of China gave further fillip to Divi’s fortunes. So today, we maintain 50% SELL on valuation concern and hold the rest for positive surprise if any. Because we have bought at very good prices, our risk is limited, while late entrants are vulnerable to poor returns even if growth materializes.
Note: Margin of safety and reasonable prices lies at the core of our investment philosophy. We discourage buying stocks at very high valuation as it makes you vulnerable to steep cuts if growth rate don’t sustain. Base rates show that very few stocks manage to grow at very high rates for long.
“Investors must be willing to forego some near-term return, if necessary, as an insurance premium against unexpected and unpredictable adversity.”
Results: Divi’s Lab reported 22% growth in sales and 40% growth in operating profit year on year. We recommend to track operating cash flow of Divis’ lab versus PAT as it has large working capital requirement in terms of inventories.
APIs (forming 52% of the sales) reported 22% growth, Custom synthesis segment (forming 41% of the sales) reported 19% growth and Carotenoids reported 45% year on year.
API industry is witnessing high demand and the growth momentum is expected to continue as more opportunity shifts from China to India in medium term.
Divis’ edge comes from large scale manufacturing at lower cost, even if it means it has to hold large inventories
Outlook: Divis Labs has almost doubled it’s capacity to take advantage of large volume manufacturing. Although the company is confident to maintain steady growth led by new capacity expansions but it awaits for US FDA inspection and clearance.
MoneyWorks4me Opinion: We had recommended BUY on Divis Labs at 650/share. Buying early and at discount prices leads to positive surprises.Currently we see that capacity addition will lead to better sales growth next two years but current prices already factor in very steep growth.
We had recommended 50% SELL recommendation near 1600/share based on then expected growth rate. However, benefits from supply chain moving out of China gave further fillip to Divi’s fortunes. Even after assuming 25% growth over next 2 years, Divi’s labs trades at steep 35x EV/Operating Cash flow with leaves very limited margin of safety. We maintain 50% SELL and hold the rest for positive surprise if any.
Note: Margin of safety and reasonable prices lies at the core of our investment philosophy. This not only increases our upside potential but also give limited downside over long term.
We discourage buying stocks at very high valuation as it makes you vulnerable to steep cuts if growth rate don’t sustain. Base rates show that very few stocks manage to grow at very high rates for long.
“Investors must be willing to forego some near-term return, if necessary, as an insurance premium against unexpected and unpredictable adversity.”
APIs (forming 52% of the sales) reported 54% growth, Custom synthesis segment (forming 41% of the sales) reported 49% growth and Carotenoids reported 20% year on year.
API industry is witnessing high demand and the growth momentum is expected to continue as more opportunity shifts from China to India in medium term.
The green field manufacturing site of the company in Kakinada is yet to be resolved by the state Govt and hence the uncertainty remains.
In order to fight against Covid, Divis has developed manufacturing capability for Remdesivir intermediates. These products haven’t contributed in Q1 but could surprise positively going ahead, considering its cost-effective manufacturing.
Outlook: Divis Labs capitalized assets worth Rs 870 Cr (including a large portion of backward integration project worth Rs 300 Cr and effluent treatment augmentation project worth Rs 190 Cr). The balance capex of Rs 920 Cr is carried forward and is expected to be completed by FY21. Although the company is confident to maintain steady growth led by new capacity expansions but it awaits for US FDA inspection and clearance.
MoneyWorks4me Opinion: We had BUY on Divis Labs at 650/share.Currently we see that capacity addition will lead to better sales growth next year but current prices already factor in very steep growth. We have recommended 50% SELL recommendation near 1600/share. We remain optimistic on Divis Labs future prospects but upside from the stock is limited in our view. Even after assuming 20% growth over next 2 years, Divis trades at 2 year forward 37.5x Price to Operating Cash Flow. Since we have already sold 50%, we would wait to see any more upside surprises.
MoneyWorks4me’s employees may be invested in the securities mentioned in the above mail/report/article. For a detailed disclosure click here.
Company share prices are keep on changing according to the market conditions. The closing price of Divis Lab on 23-May-2025 16:59 is ₹6,480.7.
What is the market cap of Divis Lab?
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 23-May-2025 16:59 the market cap of Divis Lab stood at ₹1,72,042.2.
What is the P/E ratio of Divis Lab?
The latest P/E ratio of Divis Lab as of 23-May-2025 16:59 is 77.88.
What is the P/B ratio of Divis Lab?
The latest P/B ratio of Divis Lab as of 23-May-2025 16:59 is 11.55.
What is the 52-week high and low of Divis Lab?
The 52-week high of Divis Lab is ₹6,704.8 and the 52-week low is ₹4,100.7.
What is the TTM revenue of Divis Lab?
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Divis Lab is ₹9,198 ( Cr.) .
About Divis Laboratories Ltd
Divi’s Laboratories Limited is a Company limited by shares, incorporated and domiciled in India. The Company is engaged in the manufacture of Active Pharmaceutical ingredients (API’s), Intermediates and Nutraceutical ingredients with predominance in exports. In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management. The Company is a public limited company and the Company’s equity shares are listed in BSE Limited (BSE) and National Stock Exchange of India Limited (NSE) in India.
Business area of the company
The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.
Business Segments
Generic APIs
Custom Synthesis
Nutraceuticals
Products
Capecitabine
Carbidopa
Diltiazem HCl
Dextromethorphan Base
Dextromethorphan HBr
Fosphenytoin Sodium
Gabapentin
Iopamidol
Irbesartan
Levetiracetam
Levodopa
Mesalamine
Nabumetone
Naproxen
Naproxen Sodium
Niacin
Olmesartan Medoxomil
Phenylephrine HCl
Pregabalin
Proguanil HCl
Quetiapine Fumarate
Tamsulosin HCl
Telmisartan
Triprolidine HCl
Valacyclovir HCl
Valsartan
Venlafaxine HCl
Vigabatrin
Awards
2001:
Occupational Health and Safety Management System (OHSAS-18001)
2002:
May Day Award for Best Management
2003:
Shreshtha Suraksha Puraskar
Appreciation certificate for Meritorious performance in implementing the programmes of ‘Safe Guarding the Environment and Pollution Control’
Viswakarma Rashtriya Puraskar
2004:
Good Practice in Cleaner Production and Pollution Control
2005:
National Award for Excellence Water Management 2005
Appreciation certificate for Meritorious performance in implementing the programmes of ‘Safe Guarding the Environment and Pollution Control & Plantation work’.
May Day Award for Best Management
2006:
National Award for Excellence Water Management and Certificate for Water efficient unit.
National Award for Excellence Water Management and Certificate for Water efficient unit - Beyond the fence.
Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’.
2007:
Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’.
2008:
Appreciation certificate for ‘Best Cleaner Production Practices and Waste Minimization Techniques’ on the Occasion of the World Environment
Finalist Certificate
2009:
Certified and Awarded for ‘Best Green Belt Development’
Occupational Health and Safety Management System (OHSAS-18001:2007)
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’
2011:
Best Green Belt Development.
2012:
India Business Leader Award ‘First Generation Entrepreneur of the Year’
Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’.
2013:
ISO 14064 - 1: 2006 Green House Gas Accounting verification.
May Day award for Best Management
2014:
Winner of ‘Special Commendation’ for Golden Peacock Award for Corporate Social Responsibility
2015:
Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
May Day award for Best Management
ISO 14001: 2004 (Re-Certification) ‘Environment Management System’.
2018:
Occupational Health and Safety Management System OHSAS 1800:2007 (Re-certification)
ISO 14001 : 2018 (Re- certification) ‘Environmental Management System’.
May Day award for Best Management
Milestones
1990: Inception of Divi’s as Divi’s Research Centre(DRC)
1995: Setup First Manufacturing facility(Unit-1) near Hyderabad
2000: First USFDA Inspection
2002: Commenced New Manufacturing Facility (Unit 2) near Vishakhapatnam
2003: Divi’s Labs listed on Indian Stock Exchange
2007: Set up Nutraceuticals facility at Unit 2
2008: First MFDS(Korea) inspection
2010: Established New Research Centre at Hyderabad
2011: First EU GMP and Japan PMDA Inspection
2012: First TGA Inspection
2013: First Slovenian Medicines Agency inspection for Unit-II
2014: Divi’s reaches a milestone of 8700 employees
2014: First COFEPRIS inspection
2015: New corporate office inaugurated at Hyderabad
2015: New Pilot block with 160 Reactors and Kilo Lab
2016: First Anvisa (Brazil) inspection
2017: Divi’s reaches a milestone of 11,000 employees and becomes one of the largest employers in the combined state of Telangana/Andhra Pradesh
2017: Reaches the milestone of being one among the top 3 API manufacturers in the world and one among the top API companies in Hyderabad
2018: Market capital of $5B Reached
2018: 10 new production blocks commissioned
2018: Expanded the product portfolio to over 30 products
2019: Setting up Manufacturing plant at Kakinada
2019: Additional investment of $250M towards expansion of production blocks in Unit -I and Unit- II
Company quality is determined using minimum hurdle rate for return on capital employed and free cash flows for last 10 years.
Companies with smaller size have higher hurdle rate.
High quality stocks are important for long term investment.
Value
Valuation is computed by comparing relevant price multiples versus industry and its own history.
One unique and very important modification is our adjustment for company's financials for cyclicality and normalized profitability.
or based on whether current ratio is lower or higher than median values. See graph for better assessment.
Valuation is important for long term investment.
Actual valuation done by our Equity Analysts may differ from the Free DeciZen maker valuation. Subscribe to our premium products for more information on actual valuation
Price
Price rating is given based on stock price strength using moving averages and relative strength on shorter timeframe.
Short term time frame has little to no significance for long term investing but it can help in deciding how fast or how slow one can add a stock top your portfolio.
Only after a stock satisfies Quality and Value parameters, use price trend to build a position. Add slowly if price trend is Red or Orange. Add quickly if price trend is Green.
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:
Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.
MoneyWorks4Me method for rating and ranking mutual funds for SIP
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and
ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the
various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Performance Consistency: This is measure based on whether the fund has beaten the benchmark index consistently. For
this we compare the 3-year rolling returns of the fund with the benchmark for a minimum of 5 years and preferable 10
years. The period of rolling is one month and holding period is 3 years. Fund are color-coded Green on Performance when
the fund beats the benchmark more than 90% of the time. It is Orange if it beats 80% to 90% of the time and Red if less
than 80%. Funds with less than 5 year data are color-coded Grey.
Quality of Portfolio Holding: Moneyworks4Me has color-coded stocks as Green, Orange and Red based on whether the
company's performance has generated a ROCE above a threshold level (cost of capital) over 10 years (minimum 6 years) and
generated positive Free Cash Flow. For Banks it checks whether ROE is greater than 15% and sales has grown over previous
year. Stocks that perform consistently on these combined metrics are color-coded Green (min score 14 out of 20), Orange
(between 8 and 14) and Red (less than 8 out of 20).
Fund are color-coded Green provided the portfolio has 70% holding in Green stocks but not more than 20% in Red stocks.
Funds with more than 20% Red stocks in the portfolio are color-coded Red. The rest are Orange funds
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The
ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number
that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Looking to make the most of market corrections and volatility?
Did you know that market corrections can actually present great opportunities to buy high-quality stocks at discounted prices? By taking advantage of these times of volatility, you can position your portfolio for long-term growth.
At MoneyWorks4me Portfolio Advisory, we specialize in helping investors navigate market fluctuations and build a strong, diversified portfolio. With our collaborative approach, you can maintain control over your investments while benefiting from our expertise and guidance.
If you're interested in learning more and with a minimum portfolio size of 25 L+, we can help you manage your portfolio, no matter the size. let's connect and discuss how we can work together. And as a bonus, we're offering a FREE Portfolio Review using our "Portfolio Manager" tool during our conversation.
So why wait?
Let's get started today and take your portfolio to the next level!
Best Buy Stocks
Do you want to Invest in Undervalued Handpicked stocks and earn high Returns?
Why Buy Quality Stocks
Winning and long lasting portfolio is made of Quality Stocks, but how simple is that?
Important Questions while Buying Stocks
As an Investor most important decision making questions are?
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
You can make an informed decision based on:
Q : Quality :- Q Very Good
Q Somewhat Good
Q Not Good
V : Valuation:- V+UnderValued (UV) V Somewhat UV
V Fair Value
V Somewhat OV
V+ OverValued (OV)
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Make an informed decision for Funds
You can make an informed decision based on:
P : Performance (%)* 14 Very Good
14 Somewhat Good
12 Not Good
Less than 5 year data
Q : Quality of Holding Q Very Good
Q Somewhat Good
Q Not Good
*Color code for outperformance consistency
*Number is average 3 year rolling returns
×
Want to invest successfully in stocks?
How the heck do you select a solution that ensures it?
Does it get you focused on meeting your financial goals?
Does it get you focused on meeting your financial goals?
Investing is to means to funding your goals. Your solution must help you get clarity of your goals and how you should invest to reach them. Does your solution include Financial Planning?